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At the Kyoto University Research Reactor Institute (KURRI), a clinical study of boron neutron 
capture therapy (BNCT) using a neutron irradiation facility installed at the research nuclear 
reactor has been regularly performed since February 1990. As of November 2014, 510 clinical 
irradiations were carried out using the reactor-based system. The world’s first accelerator-based 
neutron irradiation system for BNCT clinical irradiation was completed at this institute in early 
2009, and the clinical trial using this system was started in 2012. A shift of BCNT from special 
particle therapy to a general one is now in progress. To promote and support this shift, 
improvements to the irradiation system, as well as its preparation, and improvements in the 
physical engineering and the medical physics processes, such as dosimetry systems and quality 
assurance programs, must be considered. The recent advances in BNCT at KURRI are reported 
here with a focus on physical engineering and medical physics topics. 
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I. INTRODUCTION 
Boron neutron capture therapy (BNCT) is a noninvasive therapeutic modality for treating locally 
invasive malignant tumors [1]. It is performed according to a two-step procedure: (1) the patient is 
injected with a tumor-localizing drug containing boron, and (2) the target volume is irradiated with 
thermal or epi-thermal neutrons. In this therapy, the following nuclear reaction is used: 
 
10B + n → 7Li + α + 2.79 MeV (6.1%) 
                                                   → 7Li* + α + 2.31 MeV (93.9%) 
                                                            → 7Li + γ + 0.48 MeV. 
 
The ranges of the α and the Li-7 particles generated in this reaction are approximately 8 and 5 μm in 
tissue, respectively.  The world’s first clinical irradiation using BNCT was carried out using a neutron 
irradiation field installed at a research nuclear reactor in the USA in 1951 [2]. From 1951 until 2012, 
BNCT has only been performed using reactor-based irradiation systems [3-12]. 
At the Kyoto University Research Reactor Institute (KURRI), BNCT clinical studies using a thermal 
neutron irradiation facility installed at the Kyoto University Reactor (KUR) came to be regularly 
performed from February 1990. At first, BNCT at this institute was performed only for malignant brain 
tumors with a craniotomy and for malignant melanomas [13]. The application was extended to head 
and neck tumors in 2001 [14], to brain tumors without a craniotomy in 2002 [15], and to body tumors 
such as those in the liver, lung, and malignant pleural mesothelioma in 2005 [16, 17]. It may be said 
that the current development of BNCT is supported by these wider applications. Although there were 
several interruption periods, 510 clinical irradiations had been carried out using this reactor-based 
system as of November 2014. 
Concurrently with the clinical study using this reactor-based system, the development of the 
accelerator-based system has been on-going [18-22]. In early 2009, the world’s first accelerator-based 
system for BNCT clinical irradiations, known as the “Cyclotron-Based Epi-thermal Neutron Source” 
(C-BENS) was completed [23]. The clinical trial using C-BENS was started in 2012. 
At present, research and development of accelerator-based irradiation systems for BNCT are 
underway at several institutions [24-27]. In Japan, BNCT using various accelerator-based irradiation 
systems including C-BENS may be carried out at multiple facilities in the near future. Clearly, a shift 
of BCNT from special particle therapy to a general one is in progress. To promote and support this shift, 
improvements to the irradiation system, as well as its preparation, and improvements in the physical 
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engineering and the medical physics processes, such as dosimetry systems and quality assurance 
programs, must be considered. In this paper, the history and recent advances in BNCT at KURRI are 
reported with a focus on physical engineering and medical physics topics. 
 
II. HISTORY OF BNCT AT KURRI 
KURRI was established in 1963. The first clinical study of BNCT at the thermal neutron irradiation 
facility at the KUR was performed in May 1974 [28]. Regular BNCT clinical irradiations at this facility 
started in February 1990. Sixty-one BNCT clinical irradiations were performed during the 6 years until 
November 1995. In the period from 1974 to 1995, only thermal neutron irradiations could be 
performed at this facility, so BNCT was only applied in cases of malignant melanomas and brain 
tumors with a craniotomy. 
From 1995 to 1996, the thermal neutron irradiation facility at the KUR was remodeled into the 
Heavy Water Neutron Irradiation Facility (HWNIF) to advance BNCT [7]. At the remodeled facility, 
neutron irradiations for various neutron energy spectra from almost-pure thermal to epi-thermal became 
available. 
The BNCT clinical study using solo-irradiations with thermal neutrons was restarted in November 
1996. Mixed irradiations using thermal and epi-thermal neutrons were started in 1997. Twenty-one 
BNCT clinical irradiations were performed during the 5 years until June 2001. From 1996 to 2001, 
BNCT using thermal neutrons was applied to treat malignant melanomas, and BNCT using the mixed 
neutron irradiation mode was applied to treat brain tumors with a craniotomy. 
In December 2001, the first BNCT treatment in the world for a head and neck tumor was carried out 
by using epi-thermal neutrons [14]. In June 2002, BNCT for brain tumors without a craniotomy began 
[15]. In 2005, wider application was promoted for tumors of the body such as tumors in the liver and 
the lung [16, 17]. During the 5 years until the KUR operation was stopped for the fuel change in 
February 2006, 193 BNCT treatments were performed. 
In February 2006, the KUR operation was stopped to change from highly-enriched uranium fuel to 
the low-enriched fuel [29]. During the operation stoppage, some minor changes to the HWNIF were 
carried out. Concurrently, the world’s first cyclotron-based irradiation system practical for BNCT (C-
BENS) was installed at our institute in 2009 [23]. 
In May 2010, BNCT clinical irradiations began simultaneously with the restart of the KUR operation. 
After the restart, 235 BNCT irradiations had been carried out as of November 2014. The clinical trial 
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using C-BENS was also started in 2012. The annual change in the number of accumulated BNCT 
irradiations using the reactor-based system in the KURRI is shown in Fig. 1. 
 
III. NEUTRON IRRADIATION SYSTEMS 
Figure 2 shows an outline of the advanced irradiation system for BNCT installed at the KUR 
concurrent with the remodeling of the KUR-HWNIF from 1995 to 1996 [7]. Clinical irradiations under 
the 5-MW full-power continuous KUR operation can be performed by employing a radiation shielding 
system consisting of the shielding door, the irradiation room, and the remote carrying system for the 
patient. 
The KUR-HWNIF has a heavy-water tank of approximately 2 m3 adjacent to the KUR core. The 
heavy-water tank contains an aluminum-heavy water mixture, and a neutron-energy spectrum shifter of 
heavy water with a thickness varying from 0 to 90 cm in order from the core side. Outside the spectrum 
shifter, two thermal neutron filters of 1-mm-thick cadmium are installed. The energy spectrum of the 
neutron beam can be controlled from almost pure thermal to epi-thermal within 5 minutes by remote 
control under continuous reactor operation [30]. 
As described above, the KUR operation stopped from February 2006 to May 2010 for a change from 
highly-enriched uranium fuel to low-enriched fuel [29]. Table 1 shows the beam characteristics at 5 
MW of KUR power after installation of the low-enriched fuel for three irradiation modes: thermal, epi-
thermal, and a mixture of thermal and epi-thermal neutrons. Here, the energy ranges are < 0.5 eV for 
thermal neutrons, 0.5 eV to 10 keV for epi-thermal neutrons, and > 10 keV for fast neutrons. The 
maximum change in the irradiation characteristics for the main irradiation modes with the low-enriched 
fuel was experimentally shown to be 20%. Also, we specifically confirmed that the beam quality 
changes for the fast-neutron and the gamma-ray contaminations were within ±10% and hardly 
influenced the BNCT clinical irradiation results. 
For the irradiation system using an accelerator, the neutron source changes from the reactor core to 
an accelerator target. The basic concept of neutron generation is similar between reactor-based systems 
and accelerator-based systems. The selection of key parameters, such as the nuclear reaction, type of 
accelerating particle, and accelerating energy, is important to consider. Many references describe the 
selection of neutron sources and accelerating particles and energies for BNCT [23-27, 31-35]. 
Specifically, the reaction of lithium or beryllium with a proton is thought to be more adequate for 
BCNT neutron generation because of the generated neutron energy and neutron yield. 
For the C-BENS, the nuclear reaction of 9Be(p, xn)9B with 30-MeV protons was selected [23]. 
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Figure 3 shows an outline of the C-BENS. The high-energy neutrons generated from this reaction are 
moderated to thermal and epi-thermal neutrons through a moderator consisting of lead, iron, aluminum, 
and calcium-fluoride. The incident thermal neurons and gamma-rays are reduced by cadmium and lead 
filters, respectively, resulting in an epi-thermal neutron beam adequate for BNCT. 
Table 2 compares the characteristics of the epi-thermal neutron mode of the KUR-HWNIF with that 
of the C-BENS. The beam quality of C-BENS is a little better because of the smaller contamination of 
fast neutrons and gamma-rays, and the epi-thermal neutron intensity is over two times larger than that 
of the KUR-HWNIF. The energy spectrum of the neutron beam from the C-BENS is harder than that 
from the KUR-HWNIF. The physical facilities are essentially the same as the BNCT facility; however, 
the KUR-HWNIF is used for research, and the C-BENS is intended for clinical use only. 
 
IV. BEAM CHARACTERIZATION 
For beam characterization, the neutron energy spectrum is conventionally estimated by using the 
multi-activation foil method for two main reasons [30]. The first reason is that the activation foils are 
small and do not perturb the irradiation field. The second reason is that the desired nuclear reactions 
can be selected according to the neutron energy range. However, estimating the neutron energy 
spectrum in the keV range is difficult by using this method. 
In the KURRI, Bonner’s ball method is applied to supplement the multi-activation foil method [36]. 
In this method, the moderation material and wall thickness can be chosen for the neutron energy range. 
Activation foils, mainly for the thermal neutron range, and/or a He-3 counter are used as the detector. 
In contrast to the multi-activation foil method, the Bonner’s ball detector is large enough to perturb the 
field, and the detector response function should be determined by simulation.  
For the estimate of the primary gamma-ray dose rate, a smaller detector is desired so as not to 
perturb the field, similarly to that of the neutron energy spectrum. Thermo-luminescent dosimeters 
(TLD) and/or glass detectors are commonly used for this purpose. Many kinds of TLD are well known 
to exhibit an energy response to neutrons, and a correction for this must be applied. A special type of 
TLDs, BeO enclosed in a quartz glass capsule, is used at KURRI [30]. 
Ionization chambers are also used in the measurement of neutron and gamma-ray dose rates, 
typically as online detection systems. The four main beam components, thermal neutrons, epi-thermal 
neutrons, fast neutrons, and gamma-rays, are measured separately. Chambers are selected while 
considering the neutron energy spectrum and the mixing ratio of gamma-rays. The wall material, wall 
thickness, and ionization gas are also selected for the four components. Typical wall materials include 
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Si3N4, polyethylene, graphite, and magnesium. A coating of Li-6-enriched LiF may be applied as 
needed. Typical ionization gasses used are CO2, N2, tissue equivalent gas, CH4 and Ar. When 
ionization chambers are used to measure the neutron dose rate, the chamber perturbation should be 
considered. 
Recently, the authors reported on developing a multi-ionization chamber system (MICS), as seen in 
Fig. 4 [37]. The wall material, wall thickness, and ionization gas are selected specially for each 
component as follows: (1) a Si3N4 wall and N2 gas for thermal neutrons, (2) a Si3N4 wall coated with 
LiF enriched with Li-6 and N2 gas for epi-thermal neutrons, (3) a polyethylene wall and CH4 gas for 
fast neutrons, and (4) a graphite wall and argon gas for gamma-rays. Signals from the four chambers 
are arithmetically operated on with Cramer’s formula. 
Activation foils and TLDs are commonly used to estimate the dose distribution in-phantom [38]. Au 
foils with and without a Cd cover are typically used for thermal and epi-thermal neutrons and In, Ni, 
and Al foils are used for fast neutrons. We should note that TLDs cannot be placed near the activation 
foils because the secondary gamma-rays generated from the foils would influence the TLD measured 
data. In addition to foils and TLDs, some studies have reported on the use of ionization chambers and 
scintillating fibers in the measurement of the dose in-phantom [39]. 
 
V. DOSE MONITORING UNDER IRRADIATION 
A MICS can also be used as a beam monitor system [37]. As described above, a MICS can monitor 
the changes in the beam characteristics by using four types of ionization chambers to separate and 
resolve the four beam components by using Cramer’s formula. This system is almost complete and will 
be used under BNCT irradiations at the KUR-HWNIF in the near future. 
For the measurement of the surface dose, a mixture of incident epi-thermal neutrons and thermal 
neutrons moderated in the patient must be considered. Separate measurements are necessary to monitor 
the intensity of the incident epi-thermal neutrons. The activation foil method using Au and Mn, as well 
as TLDs, is commonly used in the measurement of surface dose during epi-thermal neutron irradiation. 
Surface dose measurements using an online scintillating optical fiber have also been reported [39]. 
The B-10 concentration is changed according to the elapsed time. The change in the concentration is 
larger for the patients. Then, the B-10 concentration under irradiation must be estimated. Presently, 
prompt gamma-ray analysis (PGA) is used [40]. Figure 5 shows a schematic of the PGA system using 
the neutron guide tube at the KUR. Blood samples are obtained from the patient at several time points 
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after injection with the boron compound, and the average B-10 concentration is estimated from the 
PGA. 
Some online systems for estimating the B-10 concentration, such as prompt gamma-ray SPECT (PG-
SPECT), have been studied [41]. In this system, many gamma-ray detectors with high-energy 
resolution, strong neutron shielding, and precision collimator positioning are needed. As such, 
development of this system is technologically limited at present. 
Gamma-ray telescopes have also been investigated for use in online B-10 concentration detection. 
Figure 6 shows the gamma-ray telescope system installed at the KUR-HWNIF [20]. In this telescope 
system, two units are installed. During scanning, one unit is focused on the area where the tumor is, 
while the other is focused on the normal region of the body. Currently, the gamma-ray telescope system 
at the KURRI is used for liver-tumor BNCT [16]. 
 
VI. CONCLUSION 
The recent advances in BNCT at KURRI were reported, focusing on topics for physical engineering 
and medical physics. Two BNCT neutron irradiation facilities at KURRI, KUR-HWNIF and C-BENS, 
were introduced. Beam characterization and online monitoring methods were introduced. As the field 
of BNCT advances, further development of online systems is expected. 
Many plans for accelerator-based BNCT systems are taking shape, but these plans have not yet been 
put into action. Recently, several research reactors have been shut down, leaving little opportunity for 
new research reactors to be constructed. Presently, BNCT is only performed at three institutes: KURRI 
in Japan, the National Atomic Energy Commission in Argentina, and the National Tsing Hua 
University in Taiwan. At the latter two institutes, only reactor-based systems are used. Shifting from 
reactor-based BNCT to accelerator-based BNCT should be promoted as soon as possible. 
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Table  1. Beam characteristics for three irradiation modes of KUR-HWNIF at 5 MW of KUR power after the 
low fuel enrichment. 
Irradiation   
mode 






neutron flux  
(cm-2s-1) 
Epi-thermal  
neutron flux  
(cm-2s-1) 
Fast  
neutron flux  
(cm-2s-1) 
Gamma-ray  




30 150 1.8×109 1.9×107 3.6×106 160 
Epi-thermal  
neutron 
0 1 3.7×107 9.1×108 5.1×107 70 
Mixed  
neutron 









Fast neutron dose 
/ epi-thermal flux 
(Gy/cm-2) 
Gamma-ray dose 
/ epi-thermal flux 
(Gy/cm-2) 






9.1×108 6.1×10-13 2.4×10-13 
Research 
and study 





1.9×109 5.8×10-13 7.8×10-14 
Clinical use 
only 
For tumors with  
sufficient experiments 


































Fig. 6. Outline of the gamma-ray telescope system installed at the KUR-HWNIF [20]. 
